Retatrutide Side Effects: What Phase 2 Trial Data Shows About the Triple Agonist

Retatrutide (also known as LY3437943) is currently in Phase 3 clinical trials. In Phase 2, published in the New England Journal of Medicine in 2023, it produced average weight loss of approximately 24% of body weight at the highest dose over 48 weeks. That number made headlines. The side effect profile received considerably less attention.

Retatrutide is what is called a triple agonist: it activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Tirzepatide activates the first two. The addition of glucagon receptor agonism is what differentiates retatrutide's mechanism and, importantly, its side effect signature.

Adding glucagon receptor activation to GLP-1 and GIP agonism has several metabolic effects. Glucagon promotes fat breakdown, increases thermogenesis (heat production), and elevates resting metabolic rate. These effects contribute to the greater weight loss observed with retatrutide versus tirzepatide at comparable doses.

They also add a unique dimension to the side effect profile: effects mediated specifically by glucagon receptor agonism rather than the GLP-1 class effects shared with semaglutide and tirzepatide.

Nausea, vomiting, diarrhoea, and constipation are the primary adverse events in Phase 2 trial data, consistent with the GLP-1 receptor agonist class. At the highest dose (12mg weekly), nausea was reported in approximately 60% of participants in some trial analyses, notably higher than the rates seen with semaglutide or tirzepatide in their respective trials.

The key qualifier: these rates were dose-dependent and significantly higher at the 8mg and 12mg dose groups than at lower doses. The starting dose and titration speed also affected GI burden: participants starting at 2mg and titrating gradually experienced fewer GI events than those beginning at 4mg.

The implication for practical use: slow titration is not just recommended with retatrutide, it is arguably more important than with semaglutide or tirzepatide given the higher GI event rates at peak doses.

This is where retatrutide diverges from tirzepatide in a meaningful way. The glucagon receptor component activates sympathetic tone, which increases heart rate. In Phase 2 data, the average resting heart rate increase at the 12mg dose was approximately 6.7 beats per minute, with individual ranges spanning wider.

The associated finding: cardiac arrhythmias were reported in 2 to 11% of participants receiving retatrutide versus 2% in the placebo group across dose levels. These were classified as non-serious in the trial reporting. But the cardiac signal is worth watching in Phase 3, and for people with any pre-existing cardiac conditions, this is a relevant consideration.

Retatrutide is not currently recommended for people with cardiac arrhythmias or conditions where sympathetic nervous system activation raises clinical concern.

At 24% average body weight loss, the lean tissue loss concern that applies to all GLP-1 agonists applies here with greater force. Losing a quarter of body weight over 48 weeks includes meaningful lean mass loss in the absence of deliberate protein prioritisation and resistance training.

One consideration specific to retatrutide's glucagon component: glucagon promotes glycogenolysis (breakdown of glycogen from muscles and liver) and has some catabolic effects on muscle tissue. The net effect of GLP-1 and GIP receptor activation on insulin and metabolic health, combined with glucagon's catabolic tendencies, requires active management to protect lean mass during a retatrutide protocol.

People using retatrutide who are not simultaneously consuming high protein and engaging in resistance training are at meaningful risk of losing substantial lean mass alongside fat.

The class-level risks from GLP-1 receptor agonism, pancreatitis, gallbladder disease, and the thyroid C-cell tumour warning, apply to retatrutide. The thyroid warning is extended by the glucagon receptor component: glucagon receptor agonists have also been associated with effects on thyroid function in some research contexts.

Retatrutide is not yet FDA approved. It is available in some markets through clinical trials and through research peptide channels. This means the Phase 3 trial programme is still ongoing, and the long-term safety data that underpins regulatory approval has not yet been compiled.

The Phase 2 data is informative. Phase 3 data from larger, longer, more diverse populations will add considerably to the safety characterisation. People accessing retatrutide outside clinical trial contexts are doing so before full regulatory review is complete.

Higher efficacy, somewhat higher GI side effects at peak doses, a more pronounced heart rate increase, and the same class-level concerns around muscle loss, pancreatitis, gallbladder disease, and thyroid. The profile is not categorically more dangerous than semaglutide or tirzepatide, but the dose-dependent GI effects and cardiac rate signal warrant greater respect during titration.

For people who have found semaglutide GI effects manageable and are considering retatrutide for greater efficacy, the transition is not always straightforward. The titration patience required at 8mg and above is real.

No long-term follow-up data equivalent to the STEP 4 or SURMOUNT 4 trials exists for retatrutide yet, given where it is in its development timeline. Based on mechanism, the expectation is that the same post-discontinuation weight regain dynamics that apply to semaglutide and tirzepatide will apply to retatrutide as well. There is no reason to believe the triple mechanism confers any special permanence to its effects once the drug is stopped.

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Retatrutide is not yet approved in most jurisdictions. Consult a qualified healthcare professional before use.